Sarah Palackdharry

Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models

Christina A. Wicker, Brian G. Hunt, Sunil Krishnan et al. · Cancer Letters · 2021 · 95 citations · Full text

Medicine, Oncology, Pharmacology +13

Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition

McKenzie Crist, Benyamin Yaniv, Sarah Palackdharry et al. · Journal for ImmunoTherapy of Cancer · 2022 · 69 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma.

Trisha M. Wise‐Draper, Matthew Old, Francis P. Worden et al. · Journal of Clinical Oncology · 2018 · 56 citations

Medicine, Oncology, Radiation Oncology +17

Phase 1 dose‐finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer

Shuchi Gulati, Janki Desai, Sarah Palackdharry et al. · Cancer · 2019 · 43 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Association of pathological response to neoadjuvant pembrolizumab with tumor PD-L1 expression and high disease-free survival (DFS) in patients with resectable, local-regionally advanced, head and neck squamous cell carcinoma (HNSCC).

Trisha M. Wise‐Draper, Vinita Takiar, Michelle Mierzwa et al. · Journal of Clinical Oncology · 2021 · 38 citations

Medicine, Oncology, Pharmacology +17